Ad­di­tion­al ex­clu­siv­i­ty for a can­cer treat­ment could cost the pub­lic $3 bil­lion, an­a­lyst says

Last week, the FDA grant­ed ad­di­tion­al ex­clu­siv­i­ty to Ea­gle Phar­ma­ceu­ti­cals’ can­cer med­i­cine Tre­an­da (ben­damus­tine hy­drochlo­ride), a de­ci­sion that ef­fec­tive­ly halts the in­tro­duc­tion of gener­ic ver­sions …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER